Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Mitapivat in Stable Sickle Cell Disease
NCT04610866Phase 2Active, not recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Dec 2020
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitapivat in sickle cell disease (SCD), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Frequency and severity of Adverse Events (AEs) and changes in clinical and laboratory parameters at 8 years. Started Dec 2020; status: active, not recruiting.
02
Drugs
mitapivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04610866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04610866.